HC Wainwright Has Weak Estimate for Palisade Bio Q3 Earnings

Palisade Bio, Inc. (NASDAQ:PALI) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Palisade Bio in a research report issued on Tuesday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.05) for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Palisade Bio’s FY2026 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.22) EPS.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Monday, August 10th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.50 million.

Other research analysts have also issued reports about the company. Weiss Ratings lowered Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, Oppenheimer began coverage on shares of Palisade Bio in a report on Thursday, July 23rd. They set an “outperform” rating and a $8.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $9.00.

Palisade Bio Stock Down 8.4%

Shares of PALI opened at $1.96 on Thursday. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.86. The company’s fifty day moving average is $1.94 and its two-hundred day moving average is $1.91. The firm has a market cap of $341.57 million, a PE ratio of -1.94 and a beta of 1.52.

Insider Activity at Palisade Bio

In other news, Director Robert Jr. Baltera purchased 25,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was acquired at an average cost of $1.96 per share, for a total transaction of $49,000.00. Following the acquisition, the director owned 461,904 shares of the company’s stock, valued at $905,331.84. The trade was a 5.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John David Finley sold 146,798 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the transaction, the chief executive officer owned 217,555 shares in the company, valued at $450,338.85. This trade represents a 40.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders bought a total of 125,000 shares of company stock valued at $250,100 over the last three months. 0.07% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. XTX Topco Ltd raised its stake in Palisade Bio by 53.8% during the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after acquiring an additional 7,584 shares during the period. Cetera Investment Advisers bought a new stake in shares of Palisade Bio in the 4th quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new position in Palisade Bio during the 4th quarter valued at approximately $26,000. Virtu Financial LLC acquired a new position in Palisade Bio during the 4th quarter valued at approximately $28,000. Finally, Atom Investors LP bought a new position in Palisade Bio during the 4th quarter worth $33,000. 11.79% of the stock is currently owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.